CytoDyn Announces FDA Clearance to Proceed with Phase 2 Clinical Trial of Leronlimab (PRO 140) for Treatment of NASH

Ads

You May Also Like

Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole

Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT OUTLINES PHASE 3 PROGRAMME ...

Mateon Therapeutics to Present at 29th Annual ROTH Conference

SOUTH SAN FRANCISCO, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), ...